317 related articles for article (PubMed ID: 34450231)
21. Targeting Sphingosine-1-Phosphate Signaling in Immune-Mediated Diseases: Beyond Multiple Sclerosis.
Pérez-Jeldres T; Alvarez-Lobos M; Rivera-Nieves J
Drugs; 2021 Jun; 81(9):985-1002. PubMed ID: 33983615
[TBL] [Abstract][Full Text] [Related]
22. The sphingosine-1-phosphate receptor: A novel therapeutic target for multiple sclerosis and other autoimmune diseases.
Mao-Draayer Y; Sarazin J; Fox D; Schiopu E
Clin Immunol; 2017 Feb; 175():10-15. PubMed ID: 27890706
[TBL] [Abstract][Full Text] [Related]
23. Sphingosine-1-phosphate and immune regulation: trafficking and beyond.
Chi H
Trends Pharmacol Sci; 2011 Jan; 32(1):16-24. PubMed ID: 21159389
[TBL] [Abstract][Full Text] [Related]
24. Morpholino Analogues of Fingolimod as Novel and Selective S1P
Stepanovska B; Zivkovic A; Enzmann G; Tietz S; Homann T; Kleuser B; Engelhardt B; Stark H; Huwiler A
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32899717
[TBL] [Abstract][Full Text] [Related]
25. Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis.
Cohen JA; Chun J
Ann Neurol; 2011 May; 69(5):759-77. PubMed ID: 21520239
[TBL] [Abstract][Full Text] [Related]
26. Therapeutic Potential of the Modulation of Sphingosine-1-Phosphate Receptors.
Delgado A; Martínez-Cartro M
Curr Med Chem; 2016; 23(3):242-64. PubMed ID: 26639095
[TBL] [Abstract][Full Text] [Related]
27. Sphingosine-1-Phosphate Receptors in the Central Nervous and Immune Systems.
Healy LM; Antel JP
Curr Drug Targets; 2016; 17(16):1841-1850. PubMed ID: 26424391
[TBL] [Abstract][Full Text] [Related]
28. Signaling through the S1P-S1PR Axis in the Gut, the Immune and the Central Nervous System in Multiple Sclerosis: Implication for Pathogenesis and Treatment.
Chatzikonstantinou S; Poulidou V; Arnaoutoglou M; Kazis D; Heliopoulos I; Grigoriadis N; Boziki M
Cells; 2021 Nov; 10(11):. PubMed ID: 34831439
[TBL] [Abstract][Full Text] [Related]
29. Molecular and neuroimmune pharmacology of S1P receptor modulators and other disease-modifying therapies for multiple sclerosis.
Kihara Y; Chun J
Pharmacol Ther; 2023 Jun; 246():108432. PubMed ID: 37149155
[TBL] [Abstract][Full Text] [Related]
30. Neuropsychiatric Systemic Lupus Erythematosus Is Dependent on Sphingosine-1-Phosphate Signaling.
Mike EV; Makinde HM; Der E; Stock A; Gulinello M; Gadhvi GT; Winter DR; Cuda CM; Putterman C
Front Immunol; 2018; 9():2189. PubMed ID: 30319641
[TBL] [Abstract][Full Text] [Related]
31. To fingolimod and beyond: The rich pipeline of drug candidates that target S1P signaling.
Chew WS; Wang W; Herr DR
Pharmacol Res; 2016 Nov; 113(Pt A):521-532. PubMed ID: 27663260
[TBL] [Abstract][Full Text] [Related]
32. Second generation S1P pathway modulators: research strategies and clinical developments.
Bigaud M; Guerini D; Billich A; Bassilana F; Brinkmann V
Biochim Biophys Acta; 2014 May; 1841(5):745-58. PubMed ID: 24239768
[TBL] [Abstract][Full Text] [Related]
33. Synthetic sphingosine 1-phosphate receptor modulators--opportunities and potential pitfalls.
Bolli MH; Lescop C; Nayler O
Curr Top Med Chem; 2011; 11(6):726-57. PubMed ID: 21261590
[TBL] [Abstract][Full Text] [Related]
34. Sphingosine 1-phosphate Receptor Modulator Therapy for Multiple Sclerosis: Differential Downstream Receptor Signalling and Clinical Profile Effects.
Chun J; Giovannoni G; Hunter SF
Drugs; 2021 Feb; 81(2):207-231. PubMed ID: 33289881
[TBL] [Abstract][Full Text] [Related]
35. The role of sphingosine 1-phosphate metabolism in brain health and disease.
van Echten-Deckert G
Pharmacol Ther; 2023 Apr; 244():108381. PubMed ID: 36907249
[TBL] [Abstract][Full Text] [Related]
36. The Sphingosine 1-Phosphate Signaling Pathway in Epilepsy: A Possible Role for the Immunomodulator Drug Fingolimod in Epilepsy Treatment.
Leo A; Citraro R; Marra R; Palma E; Paola EDD; Constanti A; De Sarro G; Russo E
CNS Neurol Disord Drug Targets; 2017; 16(3):311-325. PubMed ID: 27823573
[TBL] [Abstract][Full Text] [Related]
37. The neurobiology of sphingosine 1-phosphate signaling and sphingosine 1-phosphate receptor modulators.
Soliven B; Miron V; Chun J
Neurology; 2011 Feb; 76(8 Suppl 3):S9-14. PubMed ID: 21339490
[TBL] [Abstract][Full Text] [Related]
38. FTY720, an immunomodulatory sphingolipid mimetic: translation of a novel mechanism into clinical benefit in multiple sclerosis.
Baumruker T; Billich A; Brinkmann V
Expert Opin Investig Drugs; 2007 Mar; 16(3):283-9. PubMed ID: 17302523
[TBL] [Abstract][Full Text] [Related]
39. Individual variation of human S1P₁ coding sequence leads to heterogeneity in receptor function and drug interactions.
Obinata H; Gutkind S; Stitham J; Okuno T; Yokomizo T; Hwa J; Hla T
J Lipid Res; 2014 Dec; 55(12):2665-75. PubMed ID: 25293589
[TBL] [Abstract][Full Text] [Related]
40. Role of the S1P pathway and inhibition by fingolimod in preventing hemorrhagic transformation after stroke.
Salas-Perdomo A; Miró-Mur F; Gallizioli M; Brait VH; Justicia C; Meissner A; Urra X; Chamorro A; Planas AM
Sci Rep; 2019 Jun; 9(1):8309. PubMed ID: 31165772
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
